On March 11, 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) a pandemic. Until May 20, 2020, there were more than 4.9 million reported COVID-19 cases and 324869 deaths across more than 200 countries. Currently, there are no specific therapeutic agents for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Potential drugs for treating COVID-19 include human immunodeficiency virus (HIV) type 1 aspartate protease inhibitors, such as lopinavir and darunavir, which have been shown to inhibit SARS-CoV in vitro, the cause of SARS in humans.[@B1][@B2][@B3][@B4] Cobicistat-boosted darunavir is a boosted protease inhibitor in a fixed-dose combination that is approved for use in treating HIV type 1 infection.[@B5][@B6] Drug efficacy evaluation in cell models in vitro have revealed that darunavir is active against SARS-CoV-2.[@B2] At present, however, there are no clinical data on the use of these drugs for COVID-19.

Cobicistat-boosted darunavir is stable as a suspension,[@B7] so it was considered to be suitable for administration as a nasogastric tube to critical ill patients. Here, we evaluated the effects of darunavir-cobicistat on the clinical outcomes of critically ill patients with COVID-19 using a risk stratification model that adjusted for potential differences between the darunavir-cobicistat treated and non-darunavir-cobicistat treated individuals.

We retrospectively reviewed the medical records of all adults with laboratory-confirmed SARS-CoV-2 infection who were subsequently admitted to an intensive care unit (ICU) at one of the seven tertiary or referral hospitals in Daegu, South Korea between February 18 and April 5, 2020. A WHO guidance document defines laboratory confirmation of SARS-CoV-2 infection as a positive result of a real-time reverse transcriptase-polymerase chain reaction assay of samples obtained from nasal and pharyngeal swabs. The first part of this study was a retrospective cohort study that included all patients who were critically ill with laboratory-confirmed SARS-CoV-2 infection. Cobicistat-boosted darunavir was assigned to patients who failed other antiviral treatments or at the physician\'s discretion. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800--150 mg) therapy were compared. The second part of the investigation comprised a matched (1:2) case-control study, with the patients who did or did not receive darunavir-cobicistat therapy designated as "cases" and "controls" ([Fig. 1](#F1){ref-type="fig"}), respectively. This study was conducted in accordance with the tenets of the Declaration of Helsinki and was reviewed and approved by the Institutional Review Board at each hospital. The requirement for informed consent was waived because of the retrospective study design (IRB Number: YUH IRB 2020-03-057, IRB Institution: Yeungnam University Medical Center).

The present study included 110 critically ill patients who received intensive care for COVID-19, of whom 14 received darunavir-cobicistat treatment and 96 received other antiviral therapy.

There were no significant intergroup differences with regard to age, sex ratio, body mass index, and underlying disease/conditions between the groups who did and did not receive darunavir-cobicistat treatment ([Table 1](#T1){ref-type="table"}). Sequential Organ Failure Assessment (SOFA) scores {median score 2 \[interquartile range (IQR) 2--4\] vs. 6 \[IQR 3--8\], *p*\<0.001} and National Early Warning Scores \[median score 6 (IQR 5--7) vs. 8 (IQR 5--11), *p*\<0.001\] were significantly lower in the darunavir-cobicistat group than in the controls, indicating that the darunavir-cobicistat group had patients with milder illness. The incidence of shock and acute respiratory distress syndrome (ARDS) during hospitalization did not differ between the two groups. There were no between-group differences in the length of ICU stay or survival, although the number of deaths was significantly lower in the darunavir-cobicistat treatment group (14.3% vs. 46.9%, *p*=0.021). There were also significant differences in the numbers of patients who survived and were discharged from the ICU: 10 (83.3%) in the darunavir-cobicistat group and 29 (39.2%) in the controls (*p*=0.004). The crude mortality rates of all patients and ARDS patients in the darunavir-cobicistat group were lower than those in the controls \[odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04--0.89, *p*=0.035 and OR 0.17, 95% CI 0.04--0.79, *p*=0.024, respectively) ([Table 2](#T2){ref-type="table"}). Mortality rates after adjusting for variables, such as age ≥65 years and SOFA score, were the same in both groups. Two variables, age ≥65 years and SOFA score, were selected for propensity-score matching based on outcomes of the univariate and multivariate analyses. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group and 28 in the controls. [Table 1](#T1){ref-type="table"} shows the patient characteristics for both groups after matching the propensity scores; the two groups were balanced. The number of deaths was significantly lower in the darunavir-cobicistat group (14.3% vs. 50.0%, *p*=0.025). In the propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.09, 95% CI 0.01--0.52, *p*=0.009) ([Table 2](#T2){ref-type="table"}). Furthermore, the darunavir-cobicistat group, which comprised ARDS patients, had lower mortality than the controls (OR 0.08, 95% CI 0.01--0.50, *p*=0.008). To determine the effect of darunavir-cobicistat on COVID-19, we subjected the matched cohorts to Kaplan-Meier analysis and noted a significant between-group difference in in-hospital survival rate (*p*=0.048, respectively) ([Fig. 2](#F2){ref-type="fig"}).

To our knowledge, this is the first report to evaluate the treatment effect of darunavir-cobicistat in critically ill COVID-19 patients in whom darunavir-cobicistat therapy was associated with a significant survival benefit over standard treatment.

The mechanism of action underlying the effect of darunavir-cobicistat on SARS-CoV-2 remains to be elucidated. Several studies have evaluated the therapeutic effects of antiretroviral drugs in COVID-19, although the results are controversial. A recent randomised clinical trial by Cao, et al.[@B8] investigated the efficacy of lopinavir-ritonavir (400--100 mg, twice daily for 14 days) treatment in COVID-19 and showed no beneficial effect thereof over standard care in hospitalised adults with severe COVID-19. Regarding antiviral therapy with darunavir-cobicistat, there are no human clinical data on the use of this drug combination in COVID-19 patients, although a randomised clinical trial of darunavir-cobicistat is ongoing in China ([NCT04252274](http://clinicaltrials.gov/ct2/show/NCT04252274)).

This study has several limitations. First, because the study was retrospective, the possibility of selection bias cannot be excluded. Second, the propensity score matching method is limited because it adjusted only for observed covariates. Finally, there was a selection bias of using cobicistat-boosted darunavir only in 14 patients with physician preference and interference with other antiviral agents. Owing to this limitation, the conclusions of nonrandomised studies that use propensity scores must be assessed for consistency with other results, as well as for biological plausibility. Therefore, we suggest that preclinical studies and prospective clinical studies are needed to confirm these preliminary results.

In conclusion, darunavir-cobicistat therapy was associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection in this study. Further study of darunavir-cobicistat in relation to this highly virulent disease is needed.
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###### Baseline Demographics and Clinical Characteristics (n=110) of the Study Population
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                                        DRV-COBI treatment (n=14)   No DRV-COBI treatment                                         
  ------------------------------------- --------------------------- ------------------------- --------- ------------------------- ---------
  Median age (yr)                       71 (64--74)                 71 (63--78)               0.931     67 (62--76)               0.628
  Age ≥65 years                         11 (78.6)                   65 (67.7)                 0.543     17 (60.7)                 0.313
  Male sex                              6 (42.9)                    37 (38.5)                 0.757     10 (35.7)                 0.653
  Body mass index                       24.7 (22.0--26.6)           25.0 (22.0--27.1)         0.960     25.1 (22.2--27.1)         0.903
  Underlying diseases/conditions                                                                                                  
   Hypertension                         8 (57.1)                    47 (49.0)                 0.567     9 (32.1)                  0.120
   Diabetes mellitus                    5 (35.7)                    35 (36.5)                 0.957     7 (25.0)                  0.491
   Cardiovascular disease               1 (7.1)                     8 (8.3)                   \>0.99    5 (17.9)                  0.645
   Chronic lung disease                 1 (7.1)                     8 (8.3)                   \>0.99    3 (10.7)                  \>0.999
   Chronic renal disease                NA                          11 (11.5)                           3 (10.7)                  
   Chronic liver disease                1 (7.1)                     4 (4.2)                   0.501     1 (3.6)                   \>0.999
   Malignancy                           2 (14.3)                    8 (8.3)                   0.613     2 (14.3)                  0.590
   Connective tissue disease            NA                          NA                                  NA                        
   No underlying diseases               10 (71.4)                   69 (71.9)                 \>0.99    17 (60.7)                 0.495
  Severity of illness at admission                                                                                                
   APACHE II score                      12 (7--14)                  12 (7--14)                0.063     10 (7--14)                0.635
   SOFA score                           2 (2--4)                    6 (3--8)                  \<0.001   3 (2--5)                  0.284
   NEWS                                 6 (5--7)                    8 (5--11)                 \<0.001   6 (5--8)                  0.711
   CURB-65                              2 (1--2)                    2 (1--3)                  0.361     1 (0--2)                  0.203
  Sign at admission                                                                                                               
   Temperature, ℃                       37.5 (37.2--38.0)           37.0 (36.5--38.1)         0.385     37.3 (36.7--38.1)         0.609
   Heart rate, beats/min                78 (69--82)                 88 (76--102)              0.013     88 (81--94)               0.018
   Systolic blood pressure, mm Hg       125 (113--140)              130 (110--148)            0.775     138 (120--148)            0.273
   Mean arterial pressure, mm Hg        88 (81--97)                 83 (83--107)              0.351     97 (88--109)              0.070
   Leukocytes, cells/mm^3^              5870 (4320--9715)           7190 (5173--11340)        0.229     6580 (4950--9090)         0.626
   Lymphocytes, cells/mm^3^             1190 (630--1990)            1060 (660--1940)          0.739     1150 (813--1795)          \>0.999
   Haemoglobin, g/dL                    13.3 (12.3--14.5)           12.6 (10.6--14.0)         0.120     12.8 (11.4--13.6)         0.149
   Platelets, cells/mm^3^               239000 (158000--298000)     169500 (128500--235750)   0.101     165500 (127500--253250)   0.303
   Creatinine, mg/dL                    0.82 (0.69--1.11)           1.0 (0.7--1.4)            0.168     0.95 (0.69--1.17)         0.252
   PaO~2~/FIO~2~, mm Hg                 180 (89--251)               129 (79--195)             0.213     151 (98--262)             0.836
   Glucose, mg/dL                       150 (114--179)              150 (117--197)            0.598     150 (129--173)            0.706
   C-reactive protein, mg/dL            11.9 (5.0--19.6)            10.2 (6.0--15.2)          0.580     9.4 (6.0--16.0)           0.546
   Sodium, mmol/L                       137 (132--140)              136 (133--139)            0.689     134 (132--138)            0.857
   Potassium, mmol/L                    4.0 (3.6--4.7)              4 (3.5--4.6)              0.814     4.0 (3.4--4.5)            0.767
  Shock                                 9 (64.3)                    62 (64.6)                 \>0.99    19 (67.9)                 \>0.999
  Acute respiratory distress syndrome   13 (92.9)                   84 (87.5)                 \>0.99    26 (92.9)                 \>0.999
  Treatment during study period                                                                                                   
   Vasopressors                         9 (64.3)                    66 (68.8)                 0.764     19 (67.9)                 \>0.999
   Mechanical ventilation               10 (71.4)                   69 (71.9)                 \>0.99    20 (71.4)                 \>0.999
   High-flow nasal cannula              9 (64.3)                    49 (51.0)                 0.354     15 (63.6)                 0.508
   Renal replacement therapy            2 (14.3)                    19 (19.8)                 \>0.99    3 (10.7)                  \>0.999
   ECMO use                             2 (14.3)                    17 (17.7)                 \>0.99    2 (7.1)                   0.590
   Adjuvant corticosteroid use          8 (57.1)                    80 (80.3)                 0.033     22 (78.6)                 0.169
   Lopinavir-ritonavir                  8 (57.1)                    88 (91.7)                 0.002     24 (85.7)                 0.059
   Hydroxychloroquine                   13 (92.9)                   86 (89.6)                 \>0.99    25 (89.3)                 \>0.999
   Length of DRV/COBI treatment         6 (4--8)                    NA                                  NA                        
  Length of ICU stay, days              13 (7--40)                  15 (5--32)                0.618     13 (4--23)                0.320
  Death                                 2 (14.3)                    45 (46.9)                 0.021     14 (50.0)                 0.025

DRV-COBI, darunavir-cobicistat; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; NEWS, National Early Warning Scores; PaO~2~, Partial pressure of oxygen in the arterial blood; FiO~2~, percentage of inspired oxygen; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; NA, not applicable.

Data are presented as a median (interquartile range) or n%.

^\*^*p* value of DRV-COBI treatment vs. no DRV-COBI treatment, before matching, ^†^*p* value of DRV-COBI treatment vs. no DRV-COBI treatment, after matching.

###### Adjusted Effects of Mortality
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                   Crude               Adjusted mortality   Propensity-matched                               
  ---------------- ------------------- -------------------- -------------------- ------- ------------------- -------
  All patients     0.20 (0.04--0.89)   0.035                0.32 (0.06--1.62)    0.169   0.07 (0.01--0.52)   0.009
  Subgroup, ARDS   0.17 (0.04--0.79)   0.024                0.22 (0.04--1.10)    0.065   0.08 (0.01--0.50)   0.008

ARDS, acute respiratory distress syndrome; CI, confidence interval; OR, odds ratio.

^\*^Adjusted aged ≥65 years, Sequential Organ Failure Assessment score.

[^1]: ^\*^Eun Jin Kim and Sun Ha Choi contributed equally to this work.
